The healthcare company has applied for FDA Breakthrough Therapy Designation for its oral gallium maltolate therapy, a potential treatment for recurrent or refractory glioblastoma.
The healthcare technology company has announced it will hold its Annual General Meeting on 22nd May 2025.
The healthcare technology company reported strong revenue growth and significantly reduced losses in 2024, with the addition of a major new sales partner and a post-year end fundraise.
The healthcare company reports promising preliminary data from an ongoing Phase 1 study of an oral treatment for recurrent glioblastoma patients.
The healthcare technology company has raised £250,000 through a discounted placing, potentially signaling low investor appetite and ongoing funding challenges.
Healthcare technology firm unveils AI-powered imaging solutions and advances glioblastoma drug trial
The healthcare company has appointed a renowned brain tumor expert to its board, aiming to bolster its expertise and networks in this area as it develops new treatments and imaging solutions.
The healthcare company has filed a new patent application and reported strong revenue growth, driven by software sales. The firm is also making progress on a clinical trial and seeking funding for the next phase.
The healthcare technology company has reported that investment firm Braveheart Investment Group plc has acquired a 29.51% stake.
The healthcare technology company provides a comprehensive update on its clinical trials, product pipeline, and regulatory milestones, with a mix of positive and negative developments.